Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

Kisunla (1)

Anti-amyloid beta (Aβ) monoclonal antibody (1) · targets pyroglutamated Aβ in plaques (1)

None (1)

Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1)

700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1)

350 mg/20 mL vial for IV infusion (1)

1400 mg q4w (1)

IV infusion every 4 weeks (1)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

Treatment can be discontinued upon achieving amyloid clearance (1)

~12.1 days (1)

100% (IV) (1)

Limited data (1)

Rx; ARIA monitoring required (1)